42CiX Biopharma42C info
$0.02info3.85%24h
Global rank31059
Market cap$15.96M
Change 7d-
YTD Performance-40.00%
SP500 benchmarkUnderperform
P/E0
P/S3.50
Revenue$4.56M
Earnings-$7.42M
Dividend yield-
Main Sector
Healthcare

iX Biopharma (42C) Stock Overview

iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, Europe, the United States, China, and Australia. The company operates through Pharmaceutical and Nutraceutical segments. It offers Wafermine, a sublingual ketamine wafer, which has completed phase-2 clinical trial for the treatment of acute moderate to severe pain and complex regional pain syndrome; Xativa, a sublingual cannabidiol wafer, as well as Hypera, a tetrahydrocannabinol sublingual wafer for the treatment of anxiety, chronic pain, inflammation, and insomnia; and Wafesil and Silcap for the treatment of male erectile dysfunction. The company also provides LumeniX, a sublingual glutathione wafer for skin brightening and immunity; Radiance for reducing wrinkles, smoothening the skin, and promoting a youthful complexion; Regenerate that supports cellular health and aids energy production; WafeRest for the alleviating jetlag and promotion of sleep; and SL-NAD+ supplement products. In addition, it is involved in the development BnoX, a sublingual buprenorphine wafer that is in a phase-1 clinical trial for the management of moderate to severe pain; Dexmedetomidine, which has completed phase-1 clinical trial for agitation in dementia patients; Dronabinol for chemotherapy-induced nausea, vomiting, and anorexia associated with weight loss in patients with HIV/AIDS; IXB-214, which is in phase-1 clinical trial for the treatment of complex regional pain syndrome; IXB-314 that is in phase-1 clinical trial for the treatment-resistant depression; IXB-321, a sublingual vaccine wafer; iXB-322 for respiratory viral prophylaxis; and iXB-320 for anorexia in HIV/chemoinduced nausea and vomiting. iX Biopharma Ltd. was incorporated in 2004 and is headquartered in Singapore.

42C Stock Information

Symbol
42C
Address
No. 14-01 Great World City East LobbySingapore, 237994Singapore
Founded
-
Trading hours
9:00 AM - 5:00 PM SGT
Website
https://www.ixbiopharma.com
Country
🇸🇬 Singapore
Phone Number
65 6235 2270

iX Biopharma (42C) Price Chart

-
Value:-

iX Biopharma Overview: Key Details and Summary

Stock data
2023
Change
Price
$0.0208301188088258
N/A
Market Cap
$15.96M
N/A
Shares Outstanding
766.30M
2.70%
Employees
0
N/A
Shareholder Equity
15.85M
-19.71%
Valuation
2023
Change
P/S Ratio
3.50
N/A
P/B Ratio
1.01
N/A
Growth
2023
Change
Return on Equity
-0.4679
N/A
Earnings
2023
Change
Revenue
$4.56M
N/A
Earnings
-$7.42M
N/A
Gross Margin
0.3924
N/A
Operating Margin
-1.61
N/A
Net income margin
-1.63
N/A
Financial Strength
2023
Change
Total Assets
$19.23M
N/A
Total Debt
$3.35M
N/A
Cash on Hand
$5.03M
N/A
Debt to Equity
0.4417
28.85%
Cash to Debt
$1.50
-50.94%
Current Ratio
$1.53
-28.64%
logo
Facebook Icon
Twitter Icon
Linkedin Icon
© 2024 Topstocks.org